Industry Insights

DEA Telemedicine Proposed Rule Anticipation

A Virginia Senator has urged Congress to prepare to take action following reports that the DEA is considering an updated new rule that may substantially limit patients’ access to controlled substances via telehealth.

Christopher Maniscalco and Arielle Miliambro discuss the anticipated restrictions and what lies ahead for providers in a new article. Read here.

Pre-Payment Reviews Are Becoming More Challenging to Providers and Horizon Blue Cross Blue Shield of New Jersey Leads the Way

Pre-payment reviews have become a significant issue for healthcare providers, leading to delayed reimbursements and potential legal risks. Horizon Blue Cross Blue Shield of New Jersey has been particularly problematic with its "Claim Pattern Review Program."

Learn more in a new article by Guillermo Beades and Phoebe Nelson here.

DOJ Mergers & Acquisitions Safe Harbor Policy

In October of 2023, the DOJ introduced a voluntary disclosure policy with respect to corporate mergers and acquisitions, impacting providers, pharmacies, and MCOs. In effect, companies that discover criminal misconduct and disclose it within six months post-closing, while paying required penalties, can avoid a criminal guilty plea. 

Learn more in an article by Michael Sheflin here.

Oncology Practice Audits: What You Need to Know and How to Prepare

Oncology practices are experiencing an alarming surge in audits, often resulting in substantial overpayment demands due to minor documentation, coding, or credentialing issues.

Guillermo Beades and Phoebe Nelson shed light on select services that have attracted intense focus in oncology audits over the past few years. Additionally, they discuss the nuances of documentation requirements and how your practice can prepare for an audit. Read here.

Reminder: Corporate Transparency Act Deadline Approaching

The Corporate Transparency Act (CTA) requires certain entities to report ownership information to the Financial Crimes Enforcement Network (FinCen). Entities formed before January 1, 2024, must report ownership details by December 31, 2024, or face penalties of up to $500 per day. 

Read our latest article by Antony Kamel for more information here.

On-Demand Webinars

Mastering GLP-1 Compounding Series Q&A Roundup

Frier Levitt’s healthcare and pharmacy law attorneys, Dae Y. Lee, Arielle Miliambro and Dr. Martha Rumore present a follow-up webinar “Mastering GLP-1 Compounding Series Q&A Roundup,” where they tackle key issues based on the most pressing questions from our recent GLP-1 Compounding Series.

Listen in to learn more about GLP-1 compounding, legal updates, critical topics ranging from due diligence in pharmacy operations, to compounding regulations.

Click the image below to view the webinar:

Preparing for a Private Equity Transaction

Frier Levitt is excited to offer this informative webinar to help medical practices understand what it takes to prepare for a private equity transaction. Presented by Frier Levitt Co-Founding Partner Daniel Frier, and Partners Charles Newman and Timothy Norton, this webinar will provide attendees with valuable insights and guidance on how to successfully navigate the process.

Click the image below to view the webinar:

340B & Telehealth: Regulatory Considerations

In this webinar, Frier Levitt attorneys Jesse Dresser, Arielle Miliambro, and Maria Stahl provide an in-depth overview of the 340B Drug Pricing Program and its intersection with innovative telehealth arrangements. This presentation highlights the complex regulatory landscape and underscores the importance for stakeholders to stay informed about legal developments and proposed changes.

Click the image below to view the webinar:

Newsworthy

Frier Levitt Successfully Reverses Revocation of Medicare Billing Privileges of DMEPOS Suppliers

Frier Levitt Helps Healthcare Practices Reduce Over $1.5 Million in Overpayments and Terminate Multiple Pre-Payment Reviews

Brandon Zarsky and Christopher Mayer Featured in MedCity News “A Federal Judge Struck Down FTC’s Ban on Noncompetes. What Does This Mean for Healthcare?”

Frier Levitt’s Government Investigations, Litigation & White-Collar Defense Group is comprised of seasoned professionals, including a former Assistant United States Attorney, Deputy Attorneys General, and healthcare litigators who have decades of experience defending corporate entities, executives, and healthcare and life sciences professionals for alleged healthcare violations.

Our attorneys bring a wealth of firsthand knowledge of how government agencies conduct investigations and prosecute cases. This litigation-centric experience and skillset, combined with the firm’s extensive regulatory, transactional, and clinical knowledge, work to resolve such cases successfully, often doing so before public charges are filed.

Contact Frier Levitt to speak to an attorney about regulatory concerns, government inquiries, subpoena and CID defense, as well as litigation defense.

Learn more about Frier Levitt's Government Investigations, Litigation & White-Collar Defense here.

Very truly yours,

Daniel B. Frier, Esq.

Co-Founding Partner

Frier Levitt

dbfrier@frierlevitt.com

973.618.1660

Bio | LinkedIn